Physician profile
Ali Khosravani
NPI 1801827415
$616.96
in general payments reported to CMS, 2019-2025
11 companies · $85.84 in 2025
The $85.84 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $88.30 · 2021: $35.76 · 2022: $35.10 · 2023: $31.13 · 2024: $113 · 2025: $85.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $258.42 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Sanofi Pasteur INC. | $93.86 | 2019-2024 | |
| Pfizer INC. | $58.78 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $50.34 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.44 | 2020 | |
| Sanofi-Aventis U.S. LLC | $27.85 | 2025 | |
| Seqirus USA INC | $24.22 | 2025 | Flucelvax |
| Cranial Technologies, INC | $19.08 | 2024 | Doc Band |
| Tris Pharma INC | $18.03 | 2025 | Quillivant |
| Amneal Pharmaceuticals LLC | $12.94 | 2019 | |
| Bardy Diagnostics, INC. | $8.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Khosravani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.